High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

BACKGROUND: p95HER2 is a truncated form of human epidermal growth factor receptor 2 (HER2) that confers resistance to trastuzumab in vitro, but clinical results have been conflicting to date. Given that p95HER2 levels correlate with total HER2 expression levels, which confer better outcomes, we soug...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Chumsri, Saranya, Sperinde, Jeff, Liu, Heshan, Gligorov, Joseph, Spano, Jean-Philippe, Antoine, Martine, Aspitia, Alvaro Moreno, Tan, Winston, Winslow, John, Petropoulos, Christos J, Chenna, Ahmed, Bates, Michael, Weidler, Jodi Marie, Huang, Weidong, Dueck, Amylou, Perez, Edith A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6314664/
https://ncbi.nlm.nih.gov/pubmed/29530935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1864
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia